HPTN 035 Phase II/IIb Randomised Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000 for the Prevention of Sexually Transmitted Infections in Women

Overview

Journal Sex Transm Infect

Specialty Infectious Diseases

Date 2014 Jun 6

PMID 24898857

Citations 17

Authors

M Bradford Guffey

Barbra Richardson

Marla Husnik

Bonus Makanani

David Chilongozi

Elmer Yu

Gita Ramjee

Nyaradzo Mgodi

Kailazarid Gomez

Sharon L Hillier

Salim Abdool Karim

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate the effectiveness of candidate microbicides BufferGel and 0.5% PRO 2000 Gel (P) (PRO 2000) for prevention of non-ulcerative sexually transmitted infections (STIs).

Methods: Between 2005 and 2007, 3099 women were enrolled in HIV Prevention Trials Network (HPTN) protocol 035, a phase II/IIb evaluation of the safety and effectiveness of BufferGel and PRO 2000 for prevention of STIs, including Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV). Incidences of STIs were determined by study arm, and HRs of BufferGel and PRO 2000 versus placebo gel or no gel control groups were computed using discrete time Andersen-Gill proportional hazards model.

Results: The overall incidence rates were 1.6/100 person-years at risk (PYAR) for NG, 3.9/100 PYAR for CT and 15.3/100 PYAR for TV. For BufferGel versus placebo gel, HRs were 0.99 (95% CI 0.49 to 2.00), 1.00 (95% CI 0.64 to 1.57) and 0.95 (95% CI 0.71 to 1.25) for prevention of NG, CT and TV, respectively. For PRO 2000, HRs were 1.66 (95% CI 0.90 to 3.06), 1.16 (95% CI 0.76 to 1.79) and 1.18 (95% CI 0.90 to 1.53) for prevention of NG, CT and TV, respectively.

Conclusions: The incidence of STIs was high during HIV Prevention Trials Network 035 despite provision of free condoms and comprehensive risk-reduction counselling, highlighting the need for effective STI prevention programmes in this population. Unfortunately, candidate microbicides BufferGel and PRO2000 had no protective effect against gonorrhoea, chlamydia or trichomoniasis.

Trial Registration Number: NCT00074425.

Citing Articles

Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.

Abdool Karim Q, Archary D, Barre-Sinoussi F, Broliden K, Cabrera C, Chiodi F Front Immunol. 2022; 13:1055042.

PMID: 36561760 PMC: 9763292. DOI: 10.3389/fimmu.2022.1055042.

Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project.

Lyerly A, Beigi R, Bekker L, Chi B, Cohn S, Diallo D J Int AIDS Soc. 2021; 24(12):e25846.

PMID: 34910846 PMC: 8673925. DOI: 10.1002/jia2.25846.

Identification of bile acid and fatty acid species as candidate rapidly bactericidal agents for topical treatment of gonorrhoea.

Palace S, Fryling K, Li Y, Wentworth A, Traverso G, Grad Y J Antimicrob Chemother. 2021; 76(10):2569-2577.

PMID: 34245280 PMC: 8633459. DOI: 10.1093/jac/dkab217.

Incidence and risk factors of C. trachomatis and N. gonorrhoeae among young women from the Western Cape, South Africa: The EVRI study.

Jongen V, Schim van der Loeff M, Botha M, Sudenga S, Abrahamsen M, Giuliano A PLoS One. 2021; 16(5):e0250871.

PMID: 33939747 PMC: 8092667. DOI: 10.1371/journal.pone.0250871.

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Fleming T, DeGruttola V, Donnell D Stat Commun Infect Dis. 2021; 11(1).

PMID: 33777327 PMC: 7996711. DOI: 10.1515/scid-2019-0001.

References

Pattullo L, Griffeth S, Ding L, Mortensen J, Reed J, Kahn J . Stepwise diagnosis of Trichomonas vaginalis infection in adolescent women. J Clin Microbiol. 2008; 47(1):59-63. PMC: 2620841. DOI: 10.1128/JCM.01656-08. View

Vickerman P, Foss A, Watts C . Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. J Acquir Immune Defic Syndr. 2008; 48(4):460-7. DOI: 10.1097/QAI.0b013e31817aebd6. View

Stukel T, Glynn R, Fisher E, Sharp S, Lu-Yao G, WENNBERG J . Standardized rates of recurrent outcomes. Stat Med. 1994; 13(17):1781-91. DOI: 10.1002/sim.4780131709. View

Fleming T, Richardson B . Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis. 2004; 190(4):666-74. DOI: 10.1086/422603. View

van der Elst E, Okuku H, Nakamya P, Muhaari A, Davies A, McClelland R . Is audio computer-assisted self-interview (ACASI) useful in risk behaviour assessment of female and male sex workers, Mombasa, Kenya?. PLoS One. 2009; 4(5):e5340. PMC: 2671594. DOI: 10.1371/journal.pone.0005340. View

Mayaud P, Mabey D . Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges. Sex Transm Infect. 2004; 80(3):174-82. PMC: 1744836. DOI: 10.1136/sti.2002.004101. View

Amaral E, Faundes A, Zaneveld L, Waller D, Garg S . Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception. 2000; 60(6):361-6. DOI: 10.1016/s0010-7824(99)00102-x. View

Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N . Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993; 7(1):95-102. DOI: 10.1097/00002030-199301000-00015. View

Fleming D, Wasserheit J . From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999; 75(1):3-17. PMC: 1758168. DOI: 10.1136/sti.75.1.3. View

10.

Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos M, Friedland B . Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372(9654):1977-87. DOI: 10.1016/S0140-6736(08)61842-5. View

11.

Abdool Karim S, Richardson B, Ramjee G, Hoffman I, Chirenje Z, Taha T . Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25(7):957-66. PMC: 3083640. DOI: 10.1097/QAD.0b013e32834541d9. View

12.

Richardson B, Kelly C, Ramjee G, Fleming T, Makanani B, Roberts S . Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr. 2013; 63(1):120-5. PMC: 3625489. DOI: 10.1097/QAI.0b013e31828607c5. View

13.

Kapiga S, Kelly C, Weiss S, Daley T, Peterson L, Leburg C . Risk factors for incidence of sexually transmitted infections among women in South Africa, Tanzania, and Zambia: results from HPTN 055 study. Sex Transm Dis. 2009; 36(4):199-206. DOI: 10.1097/OLQ.0b013e318191ba01. View

14.

McCormack S, Ramjee G, Kamali A, Rees H, Crook A, Gafos M . PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376(9749):1329-37. PMC: 2956883. DOI: 10.1016/S0140-6736(10)61086-0. View

15.

Patton D, Sweeney Y, Cummings P, Meyn L, Rabe L, Hillier S . Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis. 2004; 31(5):290-6. DOI: 10.1097/01.olq.0000124614.91448.d4. View

16.

Rohan L, Hillier S, Dezzutti C . Preventing the sexual transmission of HIV-1 with topical microbicides: another piece of the equation. J Infect Dis. 2007; 196(9):1285-7. DOI: 10.1086/522610. View

17.

Pinkerton S, Layde P . Using sexually transmitted disease incidence as a surrogate marker for HIV incidence in prevention trials: a modeling study. Sex Transm Dis. 2002; 29(5):298-307. DOI: 10.1097/00007435-200205000-00009. View

18.

Spencer S, Valentin-Bon I, Whaley K, Jerse A . Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis. 2004; 189(3):410-9. DOI: 10.1086/381125. View

19.

Moodley P, Sturm A . Ciprofloxacin-resistant gonorrhoea in South Africa. Lancet. 2005; 366(9492):1159. DOI: 10.1016/S0140-6736(05)67470-3. View

20.

Plummer F, Simonsen J, Cameron D, Ndinya-Achola J, Kreiss J, Gakinya M . Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991; 163(2):233-9. DOI: 10.1093/infdis/163.2.233. View